Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 14/20 | 0.61 |
| ▸ | CTSS | P25774 | 6/20 | 0.53 |
| ▸ | CTSK | P43235 | 5/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486971 | 1.00 | PTPRB (0.61) | PTPRBCTSSCTSKCTSLCTSB | |
| SCHEMBL6803159 | 1.00 | PTPRB (0.61) | PTPRBCTSSCTSKCTSLCTSB | |
| SCHEMBL13224680 | 0.94 | PTPRB (0.58) | PTPRBCTSSCTSK | |
| SCHEMBL3478075 | 0.94 | PTPRB (0.58) | PTPRBCTSSCTSK | |
| SCHEMBL6803802 | 0.88 | PTPRB (0.60) | PTPRB | |
| SCHEMBL6803810 | 0.88 | PTPRB (0.60) | PTPRB | |
| SCHEMBL6802223 | 0.88 | HDAC8 (0.64) | PTPRBCTSSCTSKCTSLCTSB | |
| SCHEMBL6802214 | 0.88 | HDAC8 (0.64) | PTPRBCTSSCTSKCTSLCTSB | |
| SCHEMBL6802520 | 0.86 | PTPRB (0.56) | PTPRB | |
| SCHEMBL18687548 | 0.86 | PTPRB (0.56) | PTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632862-B2 | Pharmaceutical compositions that modulate HPTPbeta activity | PROCTER & GAMBLE COMPANY (US) | 2009-12-15 | — | — | US | claimed |
| US-20080076764-A1 | HPTPbeta as a target in treatment of angiogenesis mediated disorders | THE PROCTER & GAMBLE COMPANY | 2008-03-27 | — | — | US | claimed |
| WO-2004074238-A1 | PHENETHYLAMINO SULFAMIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-02 | — | — | WO | claimed |
| US-20040167183-A1 | Phenethylamino sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2004-08-26 | — | — | US | claimed |
| US-20100056610-A1 | HEPTbeta AS A TARGET IN TREATMENT OF ANGIOGENISIS MEDIATED DISORDERS | Thomas, Timothy P. | 2010-03-04 | — | — | US | disclosed |
| US-7632862-B2 | Pharmaceutical compositions that modulate HPTPbeta activity | PROCTER & GAMBLE COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| US-20080076764-A1 | HPTPbeta as a target in treatment of angiogenesis mediated disorders | THE PROCTER & GAMBLE COMPANY | 2008-03-27 | — | — | US | disclosed |
| US-7226755-B1 | HPTPbeta as a target in treatment of angiogenesis mediated disorders | THE PROCTER & GAMBLE COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| WO-2004074238-A1 | PHENETHYLAMINO SULFAMIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167183-A1 | Phenethylamino sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056610-A1 | HEPTbeta AS A TARGET IN TREATMENT OF ANGIOGENISIS MEDIATED DISORDERS | TPX2, TEK, HEXB | PTPRB 212/4885CTSS 3026/4885CTSK 3407/4885 |
| US-20080076764-A1 | HPTPbeta as a target in treatment of angiogenesis mediated disorders | DCTPP1, MVD, TPX2 | PTPRB 769/4885CTSS 3222/4885CTSK 3294/4885 |
| US-20040167183-A1 | Phenethylamino sulfamic acids | PTPRM, PTPRS, PTPRE | PTPRB 13/4885CTSS 1861/4885CTSK 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.